279 POSTER Pharmacodynamic effects of seliciclib (r-roscovitine, cyc202) in patients with undifferentiated nasopharyngeal cancer (NPC) using a window trial design

Hsieh, Wen-Chaun; Peh, B.K.; Loh, Thomas; Chiao, Judy; Soo, Ross A.; Green, S.R.; Lai, Yongqing; Salto–Tellez, Manuel; Soong, Richie; Goh, Boon-Cher

doi:10.1016/s1359-6349(06)70284-1

Search citation statements

Order By: Relevance

Paper Sections

Select...

Examples Of Pd Modelling Of Biomarker Data1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating tumour cells have been used as a PD biomarker in lung cancer patients [ 31 ]. In nasopharyngeal carcinoma, a tumour linked with Epstein-Barr virus infection of the malignant cells, circulating viral load, has been used as a PD biomarker [ 32 ].…”

Section: Examples Of Pd Modelling Of Biomarker Datamentioning

confidence: 99%

Pharmacodynamic Modelling of Biomarker Data in Oncology

Jackson¹

2012

ISRN Pharmacology

View full text Add to dashboard Cite

The development of pharmacodynamic (PD) biomarkers in oncology has implications for design of clinical protocols from preclinical data and for predicting clinical outcomes from early clinical data. Two classes of biomarkers have received particular attention. Phosphoproteins in biopsy samples are markers of inhibition of signalling pathways, target sites for many novel agents. Biomarkers of apoptosis in plasma can measure tumour cell killing by drugs in phase I clinical trials. The predictive power of PD biomarkers is enhanced by data modelling. With pharmacokinetic models, PD models form PK/PD models that predict the time course both of drug concentration and drug effects. If biomarkers of drug toxicity are also measured, the models can predict drug selectivity as well as efficacy. PK/PD models, in conjunction with disease models, make possible virtual clinical trials, in which multiple trial designs are assessed in silico, so the optimal trial design can be selected for experimental evaluation.

show abstract

Section: Examples Of Pd Modelling Of Biomarker Datamentioning

confidence: 99%

Pharmacodynamic Modelling of Biomarker Data in Oncology

Jackson¹

2012

ISRN Pharmacology

View full text Add to dashboard Cite

show abstract

279 POSTER Pharmacodynamic effects of seliciclib (r-roscovitine, cyc202) in patients with undifferentiated nasopharyngeal cancer (NPC) using a window trial design

Cited by 1 publication

References 0 publications

Pharmacodynamic Modelling of Biomarker Data in Oncology

Pharmacodynamic Modelling of Biomarker Data in Oncology

Contact Info

Product

Resources

About